COMy 2021 | New approaches to the treatment of elderly myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, discusses the latest approaches in the treatment of elderly patients with multiple myeloma, highlighting recently reported data and ongoing clinical trials. The Phase II HOVON 143 study assessed ixazomib, daratumumab & low-dose dexamethasone in unfit and frail patients. The latest data shared at COMy 2021 demonstrated the triplet to be an effective regimen in this patient population, giving a good progression-free survival rate with limited toxicity. Dr Beksac talks on several ongoing trials investigating the removal/reduction of steroids from treatment regimens. Studies assessing quadruplet regimens in elderly populations are also underway, including the IMROZ study (NCT03319667) of isatuximab plus bortezomib-lenalidomide-dexamethasone (VRd) and a study of daratumumab-VRd. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Dr Beksac reports the following disclosures: participation in the CEPHEUS and IMROZ studies
